Lupus Trial, Recruiting (NCT07330245)

Lupus Trial, Recruiting NCT07330245 Sponsor: AstraZeneca Condition: Lupus

Printed from Voxsanity (voxsanity.com.au) — NCT07330245 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lupus

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have agreed and signed a form giving your permission to take part in the study
You are 18 years old or older
You have been diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoimmune disease) based on recognised 2019 medical guidelines at the time of joining the study
You are being prescribed the medication anifrolumab for SLE for the first time, following the approved guidelines and coverage rules in Italy

Who may not be able to join:

Your SLE is already considered to be in a low level of disease activity or a stable, well-controlled state at the time of joining the study (confirm with trial site)
You have previously taken the medication anifrolumab
You have been diagnosed with certain serious forms of kidney disease related to lupus, or a severe and unstable form of lupus affecting the brain or mental health, that require specific intensive treatments (confirm with trial site)
You are currently taking part in another clinical trial that involves testing an experimental treatment
You are unable to understand, read, or sign the consent form, or complete patient questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07330245

Sponsor: AstraZeneca

Phase: Not Applicable

Status: Recruiting

Condition: Lupus

Trial contact: 1-877-240-9479

More information: https://clinicaltrials.gov/study/NCT07330245

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have agreed and signed a form giving your permission to take part in the study
You are 18 years old or older
You have been diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoimmune disease) based on recognised 2019 medical guidelines at the time of joining the study
You are being prescribed the medication anifrolumab for SLE for the first time, following the approved guidelines and coverage rules in Italy

Who may not be able to join:

Your SLE is already considered to be in a low level of disease activity or a stable, well-controlled state at the time of joining the study (confirm with trial site)
You have previously taken the medication anifrolumab
You have been diagnosed with certain serious forms of kidney disease related to lupus, or a severe and unstable form of lupus affecting the brain or mental health, that require specific intensive treatments (confirm with trial site)
You are currently taking part in another clinical trial that involves testing an experimental treatment
You are unable to understand, read, or sign the consent form, or complete patient questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AstraZeneca

Registry

ClinicalTrials.gov

Start date

31 December 2025

Est. completion

30 September 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Number and percentage of patients achieving LLDAS5

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov